Afalaza tab. for resorption No. 100

Release form

Tablets are flat-cylindrical, with a scored and beveled, from white to almost white.

Packaging

20 tablets in a blister strip made of polyvinyl chloride film or aluminum foil.

5 blister packs, together with instructions for medical use, are placed in a carton box.

pharmachologic effect

Prostatic hyperplasia is a benign remedy.

Indications

Benign prostatic hyperplasia of the I and II stages.

As part of the complex therapy of acute and chronic prostatitis - as an anti-inflammatory and analgesic agent.

Dysuric disorders (frequent urge to urinate, difficulty urinating, pain and discomfort in the perineum).

Erectile dysfunction (erectile dysfunction) of various origins.

Vegetative disorders of menopause in men (weakness, fatigue, decreased physical activity, decreased libido, etc.).

Complex therapy used before and after surgery on the prostate gland.

Contraindications

Increased individual sensitivity to drug components.

special instructions

The drug contains lactose, and therefore it is not recommended to prescribe it to patients with congenital galactosemia, glucose or galactose malabsorption syndrome, or with congenital lactase deficiency.

Afalaza does not affect the ability to drive vehicles and other potentially dangerous mechanisms.

Structure

Active substances:

Affinity purified antibodies to endothelial NO-synthase - 0.006 g *

Affinity purified antibodies to prostate-specific antigen - 0.006 g *

Excipients:

lactose monohydrate, microcrystalline cellulose, magnesium stearate.

* applied to lactose in the form of a mixture of three active aqueous-alcoholic dilutions of the substance, diluted respectively 10012, 10030, 100200 times

Method of administration and dosage

Inside.

At one time - 2 tablets (keep in the mouth until completely dissolved - not during meals).

The drug is taken twice a day, in the evening and in the morning.

The recommended duration of taking the drug is 16 weeks.

With severe pain syndrome and dysuric disorders in the first 2-3 weeks of therapy, taking the drug up to 4 times a day is indicated.

If necessary, on the recommendation of a doctor, it is possible to repeat the course of treatment in 1-4 months.

Side effects

When using the drug for the indicated indications and in the indicated dosages, no side effects were detected.

Drug interactions

No cases of incompatibility with other drugs have been registered to date.

Overdose

In case of an accidental overdose, dyspeptic symptoms are possible due to the fillers included in the drug.

Storage conditions

At a temperature not higher than 25? С.

Keep out of the reach of children.

During the period of using the drug, store the blister strip in a cardboard box provided by the manufacturer.

Shelf life

3 years

Do not use after the expiration date.

Name ENG

AFALAZA

Clinical and pharmacological group

Drug for the treatment of benign prostatic hyperplasia

ATX code

Other drugs for the treatment of benign prostatic hyperplasia

Dosage

6mg

Structure

Active substances: Antibodies to endothelial NO-synthase, affinity purified - 0.006 g. * Antibodies to prostate-specific antigen, affinity purified - 0.006 g. * Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate. * Are applied to lactose in the form of a mixture of three aqueous-alcoholic dilutions of a substance, diluted respectively 10012, 10030, 100200 times

Indications

Benign prostatic hyperplasia of the I and II stages.

As part of the complex therapy of acute and chronic prostatitis - as an anti-inflammatory and analgesic agent.

Dysuric disorders (frequent urge to urinate, difficulty urinating, pain and discomfort in the perineum).

Erectile dysfunction (erectile dysfunction) of various origins.

Vegetative disorders of menopause in men (weakness, fatigue, decreased physical activity, decreased libido, etc.).

Complex therapy used before and after surgery on the prostate gland.

INN / Active ingredient

antibodies to endothelial NO-synthase affinity purified, antibodies to prostate-specific antigen affinity purified

Contraindications

Increased individual sensitivity to drug components.

Age under 18.

Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Storage conditions and periods

In a dark place at a temperature not exceeding 25 degrees.

Expiration date: 3 years

Specifications

Category

BPH

,

Impotence in men

Scope of the drug

Genitourinary system

Release form

Tablet

Manufacturer country

Russia

Package quantity, pcs

one hundred

Scope of application

Urology

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Materia Medica Holding

The amount of the dosage form in the primary package

20 pcs.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Prostate hyperplasia benign remedy

Dosage form

Lozenges

Packaging

Cardboard box

Expiration date in days

1095

The target audience

Adult

Package weight, g

ten

Mode of application

:

Inside.

At one time - 2 tablets (keep in the mouth until completely dissolved - not during meals).

The drug is taken twice a day, in the evening and in the morning.

The recommended duration of taking the drug is 16 weeks. < br> With severe pain syndrome and dysuric disorders in the first 2-3 weeks of therapy, taking the drug up to 4 times a day is indicated. < br> If necessary, on the recommendation of a doctor, it is possible to repeat the course of treatment after 1 - 4 months.

Anatomical and therapeutic characteristics

:

G04CX Drugs for the treatment of benign prostatic hypertrophy other

Dosage (volume) of the substance in the preparation

:

1 tablet contains: antibodies to endothelial NO-synthase affinity purified 0.006 g *, antibodies to prostate-specific antigen affinity purified 0.006 g * < br> * are applied to lactose in the form of a mixture of three active water-alcohol dilutions of the substance, diluted in 10012, 10030, respectively, 100-200 times.

Information on technical characteristics, delivery set, country of manufacture